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A total of 327 women were screened, amongst them, 7 (2.14%) were cytomegalovirus (CMV) DNA 
positive by polymerase chain reaction (PCR). Antibodies against toxoplasma were also detected in 106 
(32.41%) women, while 54 (16.51%) were anti CMV positive. Eleven (3.36%) and thirteen (3.97%) women 
were anti HSV and anti Rubella virus positive, respectively. High prevalence was recorded in age group 
21 to 30 years which was 2.53% (4/158), followed by the age group <20 years which was 2.27% (1/44), 
then in age group 31 to 40 years, 2.25% (2/89) CMV DNA were detected by PCR and 0% was recorded in 
age group of above 40 years. The overall prevalence of human cytomegalovirus (HCMV) infection in 16 
to 45 year-old was 2.14% by PCR and the number of abortion noted was 0 to 5 times. Active infection of 
HCMV was observed in women with number of abortion. Force of infection was significantly higher 
among age group 21 to 30 and 31 to 40 years. PCR was a more sensitive, reliable and accurate method 
for the detection of HCMV infection in pregnant women during this study. 
 





Human cytomegalovirus (HCMV) is the most common 
source of congenital malformation resulting from viral 
intrauterine infection in developed countries (Jahromi et 
al., 2010). HCMV affects 1% of all infants born in the 
USA and less than 1% of all infants born worldwide. It is 
the leading viral cause of mental retardation and the most 
frequent non-hereditary cause of sensorineural hearing 
loss (Nassetta et al., 2009). HCMV is large, with a 
genome of 235 kb encoding 165 genes (Davidson et al., 
2003). The virion consists of a double-stranded linear 
DNA core in an icosahedral nucleocapsid, enveloped by 
a proteinaceous matrix (Chen et al., 1999). These 
components are enclosed in a lipid bilayer envelope that 
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Cytomegalovirus (CMV) infection during pregnancy can 
be transmitted to the fetus, resulting in a congenital 
infection and is a leading cause of hearing loss, vision 
loss and mental retardation (Soetens et al., 2008). About 
58.9% of individuals aged 6 and above are infected with 
CMV (Staras et al., 2006). Women infected for the first 
time during pregnancy are likely to transmit CMV to their 
fetuses. More children suffer serious disabilities caused 
by congenital CMV than by several better-known 
childhood maladies such as Down syndrome or fetal 
alcohol syndrome (McCarthy et al., 2009). HCMV is the 
most common cause of congenital infection in humans 
and intrauterine primary infections are second only to 
Down's syndrome as a known cause of mental 
retardation (Ryan and Ray, 2004). 
A number of investigators are evaluating qualitative and 
quantitative CMV DNA polymerase chain reaction (PCR) 
and antigenemia assays for their abilities to diagnose 
patients with CMV disease (Hansen et al., 1994; 
Rasmussen et al.,  1995;  Wetherill  et  al.,  1996)  and  to
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Figure 1. Gel picture of amplified DNA product of CMV. Lanes 1 to 3: Negative; 




predict those at the highest level (Drouet et al., 1993; 
Shinkai et al., 1997). CMV infection diagnosis now relies 
on real-time PCR assays (Gault et al., 2001; Gouarin et 
al., 2004; Garrigue et al., 2006).  
This study was conducted to investigate the prevalence 








HCMV infection during pregnancy can be transmitted to the fetus, 
resulting in a congenital infection. This study was proposed to 
analyze/detect the active infection of HCMV by PCR in pregnant 




Source of samples 
 
A total of 327 blood samples were collected from the gynecology 
wards of Lady Reading Hospital, Peshawar and Khyber Teaching 
Hospital Peshawar, the province large hospitals where patients visit 
from different areas of Khyber Pukhtoonkhwa (formerly NWFP). 5 
CC of venous blood was taken in a sterile tube; serum was 
separated by centrifugation at 5000 rpm for 5 min. The samples 
were divided into two aliquots and were stored at -20°C and 
transported to the main Laboratory of Department of 
Biotechnology/Microbiology, KUST, where DNA was extracted from 





DNA was extracted in biosafety hood type II from all blood samples 
with the help of Ultra script DNA extraction kit (Anagen, Inc. USA) 
according to the manufacturer procedure. 100 µl serum was used 
for DNA extraction and the purified extracted DNA was re-








PCR reactions were carried out in a  thermal  cycler  (Nyxtech USA)  
with Taq DNA polymerase (Fermentas USA). The first round of 
amplification was performed with 5 µl of extracted DNA by using an 
outer sense primer and an outer antisense primer. The reaction 
mixture for a single reaction consisted of 10X PCR Buffer- 2.0 µl, 
MgCl2 (25 mM)- 2.4 µl, dNTPs (500 µM)- 1.0 µl, outer sense primer- 
1.0 µl, outer antisense primer- 1.0 µl, dH2O- 11.6 µl, Taq. DNA 
Polymérase (2 U/µl)- 1.0µ l and extracted DNA- 5.0 µl. The cycling 
conditions for regular PCR are denaturation temperature at 95°C, 






The first round amplification product were re-amplified with nested 
primers in the same thermal cycler with Taq DNA polymerase. The 
second nested round was carried out to re-amplify 5 mµl PCR 
product of the first round by using an inner sense primer and inner 
antisense primer. The reaction mixture and conditions were the 





PCR products were electrophoreses in 2% agarose gel prepared in 
0.5X TBE buffer (boiled for 2 min in microwave oven and cooled to 
50°C), adding ethidium bromide (1 µg/ml) stain and evaluated 
under ultra violet light. 
 The specific DNA product for HCMV of each sample was 
determined by identifying the 185 bp amplified DNA bands in 
comparison with the 100-bp DNA ladder (Fermentas Germany), 





The prevalence of cytomegalovirus in pregnant women was 
determined by the following formula. 
 
Prevalence (%) = (Number of anemic patients / Total number of 





The data obtained was analyzed by using statistical software 
statistix9. 




Table 1. Age wise prevalence of HCMV (no = 327). 
 
Age group 
(number of individual) 
TORCH  










1 (44) 20.45 0.00 0.00 18.18 2.27 
2(158) 13.29 5.06 2.53 31.01 2.53 
3 (89) 21.35 0.00 7.87 44.94 2.25 
4 (36) 13.89 8.33 5.56 25.00 0.00 
 





Table 2. Abortion rate and prevalence of HCMV. 
 
Number of abortion 
(number of individual) 
TORCH 










0 (163) 6.13 0.00 0.00 16.56 0.00 
1 (51) 27.45 13.73 1.96 35.29 1.96 
2 (34) 17.65 0.00 11.76 61.76 2.94 
3 (39) 23.08 10.26 12.82 48.72 5.13 
4 (22) 45.45 0.00 9.09 54.55 4.55 
5 (18) 27.78 0.00 5.56 50.00 11.11 
 




RESULTS AND DISCUSSION 
 
In this study, women that have no medical history of 
hypertension (high blood pressure), diabetes and renal 
(kidney) disease were included. A total of 327 women 
were screened, amongst them, 7 (2.14%) were CMV 
DNA positive by PCR. Antibodies against toxoplasma 
were also detected in 106 (32.41%) women, while 54 
(16.51%) were anti CMV positive. Eleven (3.36%) and 
thirteen (3.97%) women were anti HSV and anti Rubella 
virus positive, respectively. High prevalence was 
recorded in the age group of 21 to 30 years which was 
2.53% (4/158), followed by the age group of <20 years 
which was 2.27% (1/44), then by the age group of 31 to 
40 years which was 2.25% (2/89). CMV DNA were 
detected by PCR and 0% was recorded in the age group 
of >40 years (Table 1). From a total of 327 individuals, 
164 (50.15%) showed abortion rates of 1 to 5,  while  163 
(49.85%) showed  no  abortion.  Out  of  the  51  (15.6%) 
pregnant women who had abortion once, only one 
(1.96% of this group) was CMV DNA PCR positive and 
14 (27.45%) were CMV antibodies positive. Out of the 39 
(11.93%) women who had abortion thrice, two (5.13%) 
women were CMV-PCR positive and nine (23.08%) were 
CMV antibodies positive, whereas in women who had 
abortion 4 times, one (4.55%) was CMV-PCR positive 
and ten (45.45%) were CMV antibodies positive (Table 
2). 
CMV the largest and most complex member of the 
herpesvirus family that infects humans (Gouarin et al., 
2004), is named so due to the cytopathic effect resulting 
in enlarged cells having intranuclear and cytoplasmic 
inclusions (Stagno and Britt, 2006). They can be found in 
virtually every cell type of humans (Sinzger et al., 1995; 
Halwachs-Baumann et al., 1998; Hemmings et al., 1998). 
The most common known congenital viral infection is 
CMV, where in different parts of the world, its incidence 
has been estimated to be 0.2 to 2.2% of all live births 
(Fisher et al., 2000).  
PCR is the method of choice for CMV DNA 
identification which has been used in various clinical 
specimens as amniotic fluid, urine, blood and 
cerebrospinal fluid (Ross et al., 2006). In this study, we 
used TORCH for antibodies detection and PCR for CMV 
DNA detection in blood of individuals  with  age  range  of 
17 to 45 years. The CMV antibodies occurrence was 
estimated to be 16.51% and CMV DNA was detected in 
2.14% pregnant women. The high prevalence and force 
of infection indicates that CMV is easily transmitted than 
some other infections such as measles. In USA, more 
than 27,000 pregnant women experience primary CMV 
infection and are thus at high risk of giving birth to a child 
with congenital CMV infection (Stehel and Sanchez, 
2005). Special care and proper vaccination coverage are 
required to interrupt the spread of CMV (Colugnati et al., 





women who had abortion history (Edmunds et al., 2000).  
Analyzing CMV infection in different age group 
suggested that in women that are aged 16 to 45 years, 
infectivity rate is independent of age. This indicates that 
CMV transmission may be possible through these routes; 
same was also addressed by Jahromi et al. (2010). Other 
sources like non sexual close contact with urine and 
saliva may also play a major role in CMV spread (Stover 
et al., 2003). The screening of women before pregnancy 
for CMV antibodies will reduce abortion rate and also the 
number of congenitally infected infants. The transmission 
of CMV can possibly be prevented by various means 





It is clear from this study that a lot of pregnant women are 
antibodies positive against CMV and Toxoplasma which 
is suggestive of putting many unborn babies at high risk 
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